Free Samples Download Acrobat Reader $0 Co-Pay
For Healthcare Professionals
Soma Carisoprodol 250 - Relief without compromise
Soma Carisoprodol 250 - Relief without compromise

Important Information

Patient Prescribing Information

Spacer
FDA Recommended Dose
SOMA® 250 mg is for short-term use up to 2 or 3 weeks, and is recommended for patients 16 years of age and older.

Special Information for Pharmacists

When filling a prescription for SOMA 250 mg, make sure your customers are supplied with the specific dosage the physician has prescribed. When a dosage has not been specified, please check by calling the prescribing health care professional.

On this page:
Relief Comparable to SOMA 350 mg
Appropriate for Recurrent Acute Episodes


SOMA 250 mg: Comparable Relief

SOMA 250 mg builds on clinical experience with carisprodol, a trusted medication in clinical use for nearly 50 years. In clinical trials, SOMA 250 mg demonstrated comparable efficacy and relief to SOMA 350 mg with better tolerability.

Top

Appropriate for Recurrent Acute Episodes

SOMA 250 mg may be right for your patient if they...
  • Have acute episodes, but do not require chronic treatment for muscle spasms
  • Experience more than 1 acute episode throughout the year
  • Desire proven efficacy, improved tolerability, and low cost
Recurrent Acute Episodes Cycle SMR = Skeletal Muscle Relaxant

Skeletal Muscle Relaxants (SMRs) like SOMA 250 mg are used to treat recurrent acute episodes, rather than for continuous treatment of chronic musculoskeletal conditions.
Top
FDA Recommended Dose of Soma 250
spacer

References
1. SOMA [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2007
2. Data on file. Meda Pharmaceuticals Inc.


Indication:

  • SOMA (carisoprodol) is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.
  • SOMA should be used for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.

Important Safety Information:

  • SOMA is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate.
  • Patients should be advised that SOMA may cause drowsiness and/or dizziness and has been associated with motor vehicle accidents. Patients should advised to avoid using SOMA before engaging in potentially hazardous activities.
  • Since the effects of SOMA and CNS depressants (including alcohol) or psychotropic drugs may be additive, appropriate caution should be exercised with patients who take more than one of these agents simultaneously.
  • In postmarketing experience with SOMA, cases of dependence, withdrawal, and abuse have been reported with prolonged use. SOMA should be used with caution in addiction-prone patients.
  • There have been postmarketing reports of seizures in SOMA treated patients with most cases having occurred in the setting of multiple drug overdoses.
  • Most common side effects include drowsiness, dizziness and headache.

Please see accompanying full Prescribing Information

.
SOM1031 3/10

SOMA® 250 mg is manufactured by Meda Pharmaceuticals Inc.

Contact Meda | Privacy Policy | Site Map

Copyright ©2010 Meda Pharmaceuticals Inc. All rights reserved.